Menu
 
Research menu
Jump to menu

Publications:  Dr Klaus Schmierer

Filippi M, Brück W, Chard D, Fazekas F, Geurts JJG, Enzinger C, Hametner S, Kuhlmann T et al.(2019). Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol vol. 18, (2) 198-210.
10.1016/S1474-4422(18)30451-4
Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al.(2019). Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. Mult Scler Relat Disord vol. 27, 247-253.
10.1016/j.msard.2018.11.001
Eskyte I, Manzano A, Pepper G, Pavitt S, Ford H, Bekker H, Chataway J, Schmierer K et al.(2019). Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis. Mult Scler Relat Disord vol. 27, 370-377.
10.1016/j.msard.2018.11.016
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K(2018). Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry vol. 89, (12) 1266-1271.
10.1136/jnnp-2017-317411
Schmierer K, McDowell A, Petrova N, Carassiti D, Thomas DL, Miquel ME(2018). Quantifying multiple sclerosis pathology in post mortem spinal cord using MRI. Neuroimage vol. 182, 251-258.
10.1016/j.neuroimage.2018.01.052
Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K et al.(2018). e-Health and multiple sclerosis: An update. Mult Scler vol. 24, (13) 1657-1664.
10.1177/1352458518799629
Schmierer K, Miquel ME(2018). Magnetic resonance imaging correlates of neuro-axonal pathology in the MS spinal cord. Brain Pathol vol. 28, (5) 765-772.
10.1111/bpa.12648
Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G(2018). Inclusion criteria used in trials of people with progressive multiple sclerosis. Mult Scler1352458518803769-1352458518803769.
10.1177/1352458518803769
BAKER D, GIOVANNONI G, PRYCE G, AMOR S, SCHMIERER K(2018). Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. Brain
10.1093/brain/awy239
Webb EJD, Meads D, Eskyte I, King N, Dracup N, Chataway J, Ford HL, Marti J et al.(2018). A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. Patient vol. 11, (4) 391-402.
10.1007/s40271-017-0296-y
Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al.(2018). A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Mult Scler Relat Disord vol. 24, 123-128.
10.1016/j.msard.2018.06.002
Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al.(2018). Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. Mult Scler Relat Disord vol. 24, 20-27.
10.1016/j.msard.2018.05.010
Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Waubant E, Goldacre MJ(2018). Psychiatric disorders in children with demyelinating diseases of the central nervous system. Mult Scler vol. 24, (9) 1243-1250.
10.1177/1352458517719150
Cerqueira JJ, Compston DAS, Geraldes R, Rosa MM, Schmierer K, Thompson A, Tinelli M, Palace J(2018). Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?. J Neurol Neurosurg Psychiatry vol. 89, (8) 844-850.
10.1136/jnnp-2017-317509
Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K et al.(2018). Validating the portal population of the United Kingdom Multiple Sclerosis Register. Mult Scler Relat Disord vol. 24, 3-10.
10.1016/j.msard.2018.05.015
Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al.(2018). Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. Multiple Sclerosis Journal - Experimental, Translational and Clinical vol. 4, (2) 2055217318783767-2055217318783767.
10.1177/2055217318783767
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al.(2018). Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology vol. 154, (2) 253-260.
10.1111/imm.12879
Carassiti D, Altmann DR, Petrova N, Pakkenberg B, Scaravilli F, Schmierer K(2018). Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex. Neuropathol Appl Neurobiol vol. 44, (4) 377-390.
10.1111/nan.12405
Stavrou M, Francis L, Tshuma N, Schmierer K(2018). Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis. BMJ Case Rep vol. 2018,
10.1136/bcr-2017-222255
Jacobs BM, Giovannoni G, Schmierer K(2018). No Evident Disease Activity-More Than a Risky Ambition?. JAMA Neurol
10.1001/jamaneurol.2018.0829
Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K(2018). Axonal loss in the multiple sclerosis spinal cord revisited. Brain Pathol vol. 28, (3) 334-348.
10.1111/bpa.12516
Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, Lock H, Longhurst HJ et al.(2018). Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol vol. 265, (5) 1199-1209.
10.1007/s00415-018-8830-y
Keddie S, Adams A, Kelso ARC, Turner B, Schmierer K, Gnanapavan S, Malaspina A, Giovannoni G et al.(2018). No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. J Neurol vol. 265, (5) 1089-1095.
10.1007/s00415-018-8801-3
Birkl C, Carassiti D, Hussain F, Langkammer C, Enzinger C, Fazekas F, Schmierer K, Ropele S(2018). Assessment of ferritin content in multiple sclerosis brains using temperature-induced R*2 changes. Magn Reson Med vol. 79, (3) 1609-1615.
10.1002/mrm.26780
Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K(2017). Disease modification in advanced MS: Focus on upper limb function. Mult Scler vol. 23, (14) 1956-1957.
10.1177/1352458517717811
Baker D, Giovannoni G, Schmierer K(2017). Marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment. Multiple Sclerosis and Related Disorders
10.1016/j.msard.2017.09.028
Campion T, Smith RJP, Altmann DR, Brito GC, Turner BP, Evanson J, George IC, Sati P et al.(2017). FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis?. Eur Radiol vol. 27, (10) 4257-4263.
10.1007/s00330-017-4822-z
Dubuisson N, Bauer A, Buckley M, Gilbert R, Paterson A, Marta M, Gnanapavan S, Turner B et al.(2017). Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. Mult Scler Relat Disord vol. 17, 172-176.
10.1016/j.msard.2017.08.002
Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K(2017). Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurol vol. 74, (8) 961-969.
10.1001/jamaneurol.2017.0676
Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K(2017). Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler1352458517726380-1352458517726380.
10.1177/1352458517726380
Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K(2017). Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm vol. 4, (4)
10.1212/NXI.0000000000000360
BAKER D, Herrod SS, Alvarez-Gonzalez C, SCHMIERER K, Giovannoni G(2017). Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurology vol. 74, (8)
10.1001/jamaneurol.2017.0676
BAKER D, SCHMIERER K, Herrod S, Alvarez Gonzalez C, Zalewski L, Albor C(2017). Both cladribine and alemtuzumab may effect multiple sclerosis via B cell depletion. Neurology: Neuroimmunology and Neuroinflammation vol. 4, (4)
10.​1212/​NXI.​0000000000000360
Alvarez-Gonzalez C, Adams A, Mathews J, Turner BP, Giovannoni G, Baker D, Schmierer K(2017). Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis. Annals of Clinical and Translational Neurology
10.1002/acn3.410
Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D et al.(2017). Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis and Related Disorders vol. 12, 70-78.
10.1016/j.msard.2017.01.007
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K(2017). Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine vol. 16, 41-50.
10.1016/j.ebiom.2017.01.042
Albor C, du Sautoy T, Kali Vanan N, Turner BP, Boomla K, Schmierer K(2017). Ethnicity and prevalence of multiple sclerosis in east London. Mult Scler vol. 23, (1) 36-42.
10.1177/1352458516638746
Stavrou M, Smith D, Shaw P, Raciborska D, Silber E, Brex P, Giovannoni G, Schmierer K et al. (2016). REAL WORLD EXPERIENCE OF FINGOLIMOD IN MULTIPLE SCLEROSIS: THE LONDON AUDIT. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. Conference: ABN vol. 87,
10.1136/jnnp-2016-315106.160
Davis A, Turner B, Ramadhan M, Albor C, Schmierer K, Giovannoni G (2016). THE BURDEN OF BLADDER DYSFUNCTION IN MULTIPLE SCLEROSIS: A MULTI-CENTRE AUDIT. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. Conference: ABN vol. 87,
10.1136/jnnp-2016-315106.127
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Baker D, Gnanapavan S, Marta M, Giovannoni G et al. (2016). TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 87,
10.1136/jnnp-2016-315106.121
Dobson R, Ramagopalan S, Topping J, Smith P, Solanky B, Schmierer K, Chard D, Giovannoni G(2016). A Risk Score for Predicting Multiple Sclerosis. PLoS One vol. 11, (11) Article 0164992, e0164992-e0164992.
10.1371/journal.pone.0164992
Pakpoor J, Wotton CJ, Schmierer K, Giovannoni G, Goldacre M(2016). Gender identity disorders and multiple sclerosis risk: A national record-linkage study. MULTIPLE SCLEROSIS JOURNAL vol. 22, (13) 1759-1762.
10.1177/1352458515627205
Pakpoor J, Wotton CJ, Schmierer K, Giovannoni G, Goldacre MJ (2016). Gender identity disorders and multiple sclerosis risk: A national record-linkage study. Mult Scler. vol. 22, 1759-1762.
10.1177/1352458515627205
Thomson A, Giovannoni G, Marta M, Gnanpavan S, Turner B, Baker D, Schmierer K (2016). Importance of upper limb function in advanced multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 676-676.
Rejdak K, Mitosek-Szewczyk K, Prus K, Trzciniecka O, Baker D, Schmierer K, Stelmasiak Z (2016). Induction therapy of relapsing secondary multiple sclerosis using generic cladribine. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 593-594.
Gold J, Marta MC, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 188-189.
Marta M, MacManus D, Yousry T, Miller D, Altmann DR, Meier UC, Christensen T, Maruszak H et al. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 188-188.
Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Waubant E, Goldacre M (2016). Risks of psychiatric disorders in children and young adults with demyelinating diseases of the central nervous system: a national record-linkage study. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 17-17.
Petrova N, Carassiti D, Scaravilli F, Baker D, Schmierer K (2016). Synaptic loss in the MS spinal cord: a key driver of disease progression?. MULTIPLE SCLEROSIS JOURNAL. Conference: ECTRIMS 2016 Committees (UCL Institute of Neurology, London, UK) from: 14/09/2016 to: 17/09/2016, vol. 22, 80-80.
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Espasandin M, Turner BP, Gnanapavan S, Marta M, Giovannoni G et al. (2016). Treating multiple sclerosis with generic cladribine. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) vol. 22, 604-605.
Campion T, Schmierer K(2016). Re: The effect of venous anatomy on the morphology of multiple sclerosis lesions: a susceptibility-weighted imaging study. Clinical Radiology
10.1016/j.crad.2016.05.021
Giovannoni G, Marta M, Davis A, Turner B, Gnanapavan S, Schmierer K(2016). Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Practical Neurologypractneurol-2015-001-practneurol-2015-001.
10.1136/practneurol-2015-001355
Pakpoor J, Wolton C, Schmierer K, Giovannoni G, Goldacre M (2016). Gender Identity Disorders and Multiple Sclerosis Risk: A National Record-Linkage Study. NEUROLOGY. Conference: AAN vol. 86,
Raftopoulos R, Hickman S, Toosy A, Sharrack B, Mallik S, Paling D, Altmann D, Yiannakas M et al. (2016). Prognostic Factors Associated with Axonal Loss after Optic Neuritis. NEUROLOGY. Conference: AAN vol. 86,
SCHMIERER K, Albor C, du Sautoy T, Kali Vanan N, Turner BP, Boomla K(2016). Ethnicity and prevalence of multiple sclerosis in east London. Multiple Sclerosis Journal
10.1177/1352458516638746
Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC et al.(2016). Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol vol. 15, (3) 259-269.
10.1016/S1474-4422(16)00004-1
Davis A, Dobson R, Kaninia S, Giovannoni G, Schmierer K(2016). Atraumatic needles for lumbar puncture: why haven't neurologists changed?. Pract Neurol vol. 16, (1) 18-22.
10.1136/practneurol-2014-001055
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D et al.(2015). No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm vol. 2, (6)
10.1212/NXI.0000000000000158
Thomson A, Davis A, Paterson A, Giovannoni G, Schmierer K (2015). DESIGNING AN INFORMATION RESOURCE TO EXPLAIN DIAGNOSTIC LUMBAR PUNCTURE AND PROMOTE BEST PRACTICE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 86,
10.1136/jnnp-2015-312379.3
Albor C, du Sautoy T, Vanan NK, Boomla K, Schmierer K (2015). ETHNICITY AND MULTIPLE SCLEROSIS PREVALENCE IN EAST LONDON. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 86,
10.1136/jnnp-2015-312379.100
Carassiti D, Pakkenberg B, Scaravilli F, Schmierer K (2015). Cortical atrophy predicts neuronal loss in MS: a post mortem study using unbiased sampling. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 423-424.
Giovannoni G, Brex P, Sumra M, Walters E, Schmierer K (2015). Glatiramer acetate slows disability progression - results from a 6-year analysis of the UK Risk Sharing Scheme. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 800-801.
Raftopoulos R, Rangarajan A, Chen C-L, Hickman S, Toosy A, Wheeler-Kingshott CA, Altmann D, Malik S et al. (2015). Sodium channel blockade with phenytoin has a neuroprotective effect on the ganglion cell complex after acute optic neuritis. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 273-274.
Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, Giovannoni G, Miller D et al.(2015). Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol vol. 15, (4) 273-279.
10.1136/practneurol-2015-001139
Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M(2015). Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Mult Scler Relat Disord vol. 4, (4) 329-333.
10.1016/j.msard.2015.04.006
Thomson A, Davis A, Paterson A, Giovannoni G, Schmierer K (2015). Designing an information resource to explain diagnostic lumbar puncture and promote best practice. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 491-492.
Raftopoulos R, Hickman S, Toosy A, Sharrack B, Mallik S, Altmann D, Malladi P, Koltzenburg M et al. (2015). Neuroprotection with phenytoin in acute optic neuritis: results of a phase II randomised controlled trial. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 48-48.
Raciborska D, Turner B, Schmierer K (2015). Switching MS patients from natalizumab to fingolimod therapy: comparison of short and prolonged washout periods. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 350-350.
Schmierer K (2015). New Perspectives on Inflammatory CNS Disease Therapies. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 802-803.
Schmierer K(2015). Pathological and MRI markers of deterioration. MULTIPLE SCLEROSIS JOURNAL vol. 21, (6) 799-800.
Giovannoni G, Baker D, Schmierer K(2015). The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?. Mult Scler Relat Disord vol. 4, (1) 3-5.
10.1016/j.msard.2014.11.005
Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Goldacre MJ(2014). Testicular hypofunction and multiple sclerosis: Cause or consequence? Reply. Ann Neurol vol. 76, (5) 765-766.
10.1002/ana.24275
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner B, Calado-Marta M, Juliusson G, Baker D et al. (2014). CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 85,
10.1136/jnnp-2014-309236.140
Schmierer K, Marta M, Turner BP, Giovannoni G (2014). THE USE OF MAGNETIC RESONANCE IMAGING (MRI) IN THE MANAGEMENT OF MULTIPLE SCLEROSIS IN THE UK. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 85,
10.1136/jnnp-2014-309236.131
Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Goldacre MJ(2014). Testicular hypofunction and multiple sclerosis risk: a record-linkage study. Ann Neurol vol. 76, (4) 625-628.
10.1002/ana.24250
Giovannoni G, Baker D, Schmierer K(2014). Simvastatin in patients with progressive multiple sclerosis. Lancet vol. 384, (9947)
10.1016/S0140-6736(14)61621-4
Campion T, Smith P, Altmann DR, Turner BP, Evanson J, George IC, Sati P, Reich DS et al. (2014). FLAIR* for the non-invasive histological diagnosis of MS. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 289-290.
Schmierer K (2014). Repurposing drugs for disease modification in multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 35-36.
Carassiti D, Papachatzaki M, Scaravilli F, Pakkenberg B, Schmierer K (2014). The loss of neurons over the whole MS neocortex. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 59-59.
Carassiti D, Petrova N, Al-Zawawi S, Scaravilli F, Schmierer K (2014). The relationship between axonal loss and demyelination in the MS spinal cord. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 366-366.
Gnanapavan S, Jaunmuktane Z, Baruteau KP, Gnanasambandam S, Schmierer K(2014). A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome. BMC Neurol vol. 14,
10.1186/1471-2377-14-68
Wallner-Blazek M, Rovira A, Filippi M, Rocca MA, Miller DH, Schmierer K, Frederiksen J, Gass A et al.(2014). Erratum to: Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol vol. 261, (4) 848-849.
10.1007/s00415-014-7279-x
Altmann DR, Button T, Schmierer K, Hunter K, Tozer DJ, Wheeler-Kingshott CA, Coles A, Miller DH(2014). Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. Mult Scler Relat Disord vol. 3, (2) 237-243.
10.1016/j.msard.2013.09.007
Davis A, Dobson R, Kaninia S, Espasandin M, Berg A, Giovannoni G, Schmierer K(2014). Change practice now! Using atraumatic needles to prevent post lumbar puncture headache. Eur J Neurol vol. 21, (2) 305-311.
10.1111/ene.12307
Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G(2014). Assessing treatment response to interferon-beta Is there a role for MRI?. NEUROLOGY vol. 82, (3) 248-254.
10.1212/WNL.0000000000000034
Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G(2014). Assessing treatment response to interferon-β: is there a role for MRI?. Neurology vol. 82, (3) 248-254.
10.1212/WNL.0000000000000036
Papachatzaki MM, Ali N, Arshad Q, Cader S, Peppas I, Everett C, Bronstein AM, Schmierer K(2013). Progressive ataxia with oculo-palatal tremor and optic atrophy. J Neurol vol. 260, (11) 2903-2905.
10.1007/s00415-013-7136-3
Albor C, Richards O, Ramagopalan S, Boomla K, Schmierer K(2013). Using routine point-of-care data for research: the East london multiple sclerosis cohort. J Neurol Neurosurg Psychiatry vol. 84, (11)
10.1136/jnnp-2013-306573.170
Carassiti D, Papachatzaki M, Scaravilli F, Schmierer K (2013). Accurate estimates of whole brain neuronal loss in multiple sclerosis using unbiased quantitative histology. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 161-161.
Raftopoulos RE, Hickman S, Toosy A, Wheeler-Kingshott CA, Altmann D, Malik S, Paling D, Yiannakas M et al. (2013). Optical coherence tomography (OCT), visual function and MRI measures in acute optic neuritis: baseline data from a clinical trial. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 8-9.
Papachatzaki MM, Carassiti D, McDowell A, Schmierer K (2013). Stereological estimates of neuronal loss in the primary motor cortex of multiple sclerosis patients. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 571-572.
Wallner-Blazek M, Rovira A, Fillipp M, Rocca MA, Miller DH, Schmierer K, Frederiksen J, Gass A et al.(2013). Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol vol. 260, (8) 2016-2022.
10.1007/s00415-013-6918-y
Schmierer K, Papachatzaki MM(2013). A single lesion-And yet MS?. Mult Scler Relat Disord vol. 2, (3) 154-155.
10.1016/j.msard.2013.02.002
Yiannakas MC, Tozer DJ, Schmierer K, Chard DT, Anderson VM, Altmann DR, Miller DH, Wheeler-Kingshott CAM(2013). ADvanced IMage Algebra (ADIMA): a novel method for depicting multiple sclerosis lesion heterogeneity, as demonstrated by quantitative MRI. Mult Scler vol. 19, (6) 732-741.
10.1177/1352458512462074
Valdueza JM, Doepp F, Schreiber SJ, van Oosten BW, Schmierer K, Paul F, Wattjes MP(2013). What went wrong? The flawed concept of cerebrospinal venous insufficiency. J Cereb Blood Flow Metab vol. 33, (5) 657-668.
10.1038/jcbfm.2013.31
Papachatzaki MM, Ali N, Peppas Y, Cader S, Everett C, Schmierer K (2012). A NEW PHENOTYPE OF PAPT: PROGRESSIVE ATAXIA, PALATAL TREMOR AND OPTIC ATROPHY. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2012-304200a.52
Mougin OE, Mistry N, Papachatzaki MM, Gowland P, Evangelou N, Schmierer K (2012). MULTI-MODAL MRI AT 7T TO DETECT AND QUANTIFY MULTIPLE SCLEROSIS CORTICAL GREY MATTER PATHOLOGY. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2012-304200a.137
Davis A, Espasandin MD, Schmierer K (2012). OVER 100 YEARS OF POST LUMBAR PUNCTURE HEADACHE, AND COUNTING. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2012-304200a.24
Raftopoulos RE, Hickman S, Toosy A, Wheeler-Kingshott CA, Altmann D, Schmierer K, Sharrack B, Sheridan R et al. (2012). A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 442-443.
Davis A, Dobson R, Espasandin M, Giovannoni G, Schmierer K (2012). Cerebrospinal fluid biomarkers as outcome measures in clinical trials of MS: The significance of post lumbar puncture headaches. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 237-238.
Altmann DR, Button T, Schmierer K, Hunter K, Tozer D, Wheeler-Kingshott C, Coles A, Miller DH (2012). Sample sizes for lesion magnetisation transfer ratio outcome measures in remyelination trials for multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 470-470.
Filippi M, Rocca MA, Barkhof F, Brück W, Chen JT, Comi G, DeLuca G, De Stefano N et al.(2012). Association between pathological and MRI findings in multiple sclerosis. The Lancet Neurology vol. 11, (4) 349-360.
10.1016/s1474-4422(12)70003-0
Dobson R, Meier UC, Schmierer K, Giovannoni G (2012). DO SIBLINGS OF PEOPLE WITH MULTIPLE SCLEROSIS (MS) HAVE MARKERS OF MS RISK?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2011-301993.173
Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K et al.(2012). Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler vol. 18, (3) 314-321.
10.1177/1352458511421054
SCHMIERER K(2012). Magnetic resonance imaging in multiple sclerosis. Multiple Sclerosis (Visual Guide for Clinicians), Editors: Dobson, R, Giovannoni, G, Atlas Medical Publishing
Petzold A, Tozer DJ, Schmierer K(2011). Axonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter. Exp Neurol vol. 232, (2) 234-239.
10.1016/j.expneurol.2011.09.011
Dobson R, Meier UC, Schmierer K, Giovannoni G(2011). Do siblings have markers of multiple sclerosis risk?. MULTIPLE SCLEROSIS JOURNAL vol. 17, S86-S86.
Schmierer K, Tozer D, Petzold A(2011). In multiple sclerosis' protein phosphorylation competes with the free proton binding capacity in post-mortem brain tissue. MULTIPLE SCLEROSIS JOURNAL vol. 17, S503-S503.
Schmierer K, Tozer DJ, Petzold A (2011). Axonal Damage in the Making: Neurofilament Phosphorylation and Magnetization Transfer in Multiple Sclerosis Non-Lesional White Matter. NEUROLOGY. vol. 76, A358-A358.
MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, Polman CH, Schmierer K et al.(2011). BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol vol. 258, (3) 449-456.
10.1007/s00415-010-5777-z
Connolly F, Paul F, Valdueza JM, Julika F, Schmierer K, Stephan SJ (2011). Patients with Multiple Sclerosis Do Not Suffer from Cerebro-Cervical Venous Congestion. NEUROLOGY. vol. 76, A171-A171.
Ugradar SY, Parkes H, So PW, Miller DH, Jackson S, Scaravilli F, Schmierer K (2011). Quantifying Remyelination in Multiple Sclerosis Using High Field (9.4T) Magnetic Resonance Imaging. NEUROLOGY. vol. 76, A172-A172.
Schmierer K (2010). Imaging of human inflammatory neurodegenerative disorders. IMMUNOLOGY. vol. 131, 5-5.
Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ(2010). Reply. Ann Neurol vol. 68, (6)
10.1002/ana.22182
Schmierer K, Thavarajah JR, An SF, Brandner S, Miller DH, Tozer DJ(2010). Effects of formalin fixation on magnetic resonance indices in multiple sclerosis cortical gray matter. J Magn Reson Imaging vol. 32, (5) 1054-1060.
10.1002/jmri.22381
Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ(2010). Multiple Sclerosis Appears To Be Associated with Cerebral Venous Abnormalities Reply. ANN NEUROL vol. 68, (4) 561-562.
10.1002/ana.22181
Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ(2010). No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol vol. 68, (2) 173-183.
10.1002/ana.22085
Schmierer K, Parkes HG, So P-W, An SF, Brandner S, Ordidge RJ, Yousry TA, Miller DH(2010). High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain vol. 133, (Pt 3) 858-867.
10.1093/brain/awp335
Schmierer K (2009). HIGH FIELD MRI REVEALS MULTIPLE SCLEROSIS CORTICAL GREY MATTER LESIONS AND ALLOWS QUANTITATIVE ASSESSMENT OF NEURONS AND AXONS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 80,
10.1136/jnnp.2009.195180w
Parkes H, So PW, Brandner S, An S, Miller D, Yousry T, Schmierer K (2009). Quantifying cortical pathology in multiple sclerosis using high-field MRI. MULTIPLE SCLEROSIS. vol. 15, S91-S91.
Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, Khaleeli Z, Schmierer K et al.(2009). Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. NEUROLOGY vol. 73, (1) 32-38.
10.1212/WNL.0b013e3181aa29fe
Fisniku LK, Altmann DR, Cercignani M, Tozer DJ, Chard DT, Jackson JS, Miszkiel KA, Schmierer K et al.(2009). Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Mult Scler vol. 15, (6) 668-677.
10.1177/1352458509103715
Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O et al.(2009). GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology vol. 72, (9) 806-812.
10.1212/01.wnl.0000343880.13764.69
Schmierer K, Parkes HG, So P-W(2009). Direct visualization of remyelination in multiple sclerosis using T2-weighted high-field MRI. Neurology vol. 72, (5)
10.1212/01.wnl.0000341878.80395.39
Schmierer K(2008). Commentary on: "Dirty-appearing white matter in multiple sclerosis. J NEUROL vol. 255, (11) 1812-1812.
10.1007/s00415-008-0001-0
Schmierer K(2008). Commentary on: "Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss", by G. R. W. Moore, et al. in J Neurol (2008) 255: DOI 10.1007/s00415-008-0002-z. J Neurol vol. 255, (11)
Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K et al.(2008). Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet vol. 372, (9648) 1463-1472.
10.1016/S0140-6736(08)61619-0
Petzold A, Gveric D, Groves M, Schmierer K, Grant D, Chapman M, Keir G, Cuzner L et al.(2008). Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology. Exp Neurol vol. 213, (2) 326-335.
10.1016/j.expneurol.2008.06.008
Parkes H, Shorter S, So PW, Baker D, Pryce G, Giovannoni G, Schmierer K (2008). High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis. MULTIPLE SCLEROSIS. vol. 14, S86-S87.
Schmierer K, Parkes H, So PW, An SF, Brandner S, Miller DH, Yousry TA (2008). Magnetization transfer ratio: a predictor of neuronal loss in multiple sclerosis cortical gray matter?. MULTIPLE SCLEROSIS. vol. 14, S219-S220.
Schmierer K, Thavarajah JR, Parkes H, Miller DH, Tozer D (2008). Multiple sclerosis cortical grey matter changes following fixation detected by multimodal magnetic resonance imaging. MULTIPLE SCLEROSIS. vol. 14, S220-S220.
MacManus DG, Miller D, Kappos L, Gold R, Havrdova E, Limmroth V, Polman C, Schmierer K et al. (2008). The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions. MULTIPLE SCLEROSIS. vol. 14, S163-S163.
Kappos L, Miller D, MacManus D, Gold R, Havrdova E, Limmroth V, Polman C, Schmierer K et al. (2008). The efficacy of BG00012 in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2B study. NEUROLOGY. vol. 70, A83-A83.
Schmierer K, Wheeler-Kingshott CAM, Tozer DJ, Boulby PA, Parkes HG, Yousry TA, Scaravilli F, Barker GJ et al.(2008). Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. Magn Reson Med vol. 59, (2) 268-277.
10.1002/mrm.21487
Tofts PS, Jackson JS, Tozer DJ, Cercignani M, Keir G, MacManus DG, Ridgway GR, Ridha BH et al.(2008). Imaging cadavers: cold FLAIR and noninvasive brain thermometry using CSF diffusion. Magn Reson Med vol. 59, (1) 190-195.
10.1002/mrm.21456
Schmierer K, Meara SJP, Miller DH, Barker GJ, Cercignani M (2007). 3D inversion recovery fast spin echo for lesion detection in post mortem multiple sclerosis brain. MULTIPLE SCLEROSIS. vol. 13, S77-S77.
Parkes HG, So PW, Miller DH, Brandner S, Yousry TA, Schmierer K (2007). High field (9.4T) magnetic resonance reveals cortical lesions in multiple sclerosis brain. MULTIPLE SCLEROSIS. vol. 13, S72-S73.
Parkes HG, Denham M, Schmierer K (2007). High-resolution 1H NMR spectroscopy of multiple sclerosis brain. MULTIPLE SCLEROSIS. vol. 13, S251-S252.
Schmierer K, Tozer DJ, Scaravilli F, Altmann DR, Barker GJ, Tofts PS, Miller DH(2007). Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. J Magn Reson Imaging vol. 26, (1) 41-51.
10.1002/jmri.20984
Schmierer K, Wheeler-Kingshott CAM, Boulby PA, Scaravilli F, Altmann DR, Barker GJ, Tofts PS, Miller DH(2007). Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage vol. 35, (2) 467-477.
10.1016/j.neuroimage.2006.12.010
Kappos L, Gold R, Miller D, MacManus DG, Havrdova E, Limmroth V, Polman C, Schmierer K et al. (2007). Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis. NEUROLOGY. vol. 68, A276-A277.
Schmierer K, Miller DH (2006). Making sense of magnetic resonance measures in multiple sclerosis: The post mortem evidence. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 77, 1389-1389.
Kappos L, Miller DH, MacManus DG, Gold R, Havrdova E, Limmroth V, Polman CH, Schmierer K et al. (2006). BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis. MULTIPLE SCLEROSIS. vol. 12, S85-S85.
Schmierer K, Parkes HG, So PW, Miller DH, Yousry TA (2006). High field-high yield: detecting multiple sclerosis white matter lesions at 9.4 Tesla. MULTIPLE SCLEROSIS. vol. 12, S45-S45.
Kappos L, Miller DH, MacManus DG, Gold R, Havrdova E, Limmroth V, Polrnan C, Schmierer K et al. (2006). Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study. JOURNAL OF NEUROLOGY. vol. 253, 27-27.
Symms M, Jäger HR, Schmierer K, Yousry TA(2006). A review of structural magnetic resonance neuroimaging. Neuroscience for Neurologists,
Schmierer K, Tozer DJ, Boulby PA, Wheeler-Kingshott CAM, Parkes HG, Yousry TA, Tofts PS, Miller DH (2005). Changes of quantitative magnetic resonance indices following fixation in post-mortem MS brain. MULTIPLE SCLEROSIS. vol. 11, S141-S141.
Schmierer K, Tozer DJ, Scaravilli F, Tofts PS, Miller DH (2005). Short T2 relaxation: a potential marker of myelin in post-mortem multiple sclerosis brain. MULTIPLE SCLEROSIS. vol. 11, S141-S141.
Cercignani M, Symms MR, Schmierer K, Boulby PA, Tozer DJ, Ron M, Tofts PS, Barker GJ(2005). Three-dimensional quantitative magnetisation transfer imaging of the human brain. Neuroimage vol. 27, (2) 436-441.
10.1016/j.neuroimage.2005.04.031
Lim ET, Schmierer K, Grant D, Keir G, Thompson EJ, Miller DH, Giovannoni G (2005). A comparison of the immunology and histopathology in post mortem multiple sclerosis brain. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 76, 615-616.
Symms M, Jäger HR, Schmierer K, Yousry TA(2004). A review of structural magnetic resonance neuroimaging. J Neurol Neurosurg Psychiatry vol. 75, (9) 1235-1244.
10.1136/jnnp.2003.032714
Schmierer K, Scaravilli E, Tozer DJ, Tofts PS, Miller DH (2004). Magnetisation transfer as a tool to monitor multiple sclerosis: postmortem evidence. MULTIPLE SCLEROSIS. vol. 10, S229-S229.
Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH(2004). Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol vol. 56, (3) 407-415.
10.1002/ana.20202
Schmierer K, Scaravilli E, Boulby P, Wheeler-Kingshott CAM, Miller DH (2004). Pathological correlates of diffusion tenser imaging (DTI) in post-mortem MS brain. MULTIPLE SCLEROSIS. vol. 10, S229-S229.
Schmierer K (2004). Pathological substrates of quantitative MRI in post mortem multiple sclerosis brain. MULTIPLE SCLEROSIS. vol. 10, S104-S105.
Goodman A, Bar-Or A, Miller A, Miller D, Panzara M, Rossman H, Schmierer K, Toal M (2004). GLANCE: A double-blind, randomised, placebo-controlled, parallel-group safety study of natalizumab (Antegren) in combination with glatiramer acetate (Copaxone) in subjects with relapsing-remitting multiple sclerosis. JOURNAL OF NEUROLOGY. vol. 251, 176-177.
Schmierer K, Scaravilli E, Altmann DA, Barker GJ, Miller DH (2004). Magnetisation transfer ratio: a robust measure of myelin content in post-mortem multiple sclerosis brain. JOURNAL OF NEUROLOGY. vol. 251, 24-24.
Kuhle J, Hardmeier M, Hooghe MD, Schmierer K, Polman C, Achiti I, Kappos L, EUSPMS Longterm Follow-up Study Gr(2004). 8 year follow-up of the European study of Interferon beta-1b (EUSPMS) in secondary progressive MS. NEUROLOGY vol. 62, (7) A489-A490.
Schmierer K, Altmann DR, Kassim N, Kitzler H, Kerskens CM, Doege CA, Aktas O, Lünemann JD et al.(2004). Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study. Mult Scler vol. 10, (2) 182-187.
10.1191/1352458504ms996oa
Schmierer K, Scaravilli F, Barker GJ, Gordon R, MacManus DG, Miller DH(2003). Stereotactic co-registration of magnetic resonance imaging and histopathology in post-mortem multiple sclerosis brain. Neuropathol Appl Neurobiol vol. 29, (6) 596-601.
10.1046/j.1365-2990.2003.0497.x
Mottershead JP, Schmierer K, Clemence M, Thornton JS, Scaravilli F, Barker GJ, Tofts PS, Newcombe J et al.(2003). High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord. J Neurol vol. 250, (11) 1293-1301.
10.1007/s00415-003-0192-3
Grosse P, Schulz J, Schmierer K(2003). Diagnostic pitfalls in eosinophilic cryptococcal meningoencephalitis. Lancet Neurol vol. 2, (8)
10.1016/S1474-4422(03)00488-5
Schreiber SJ, Doepp F, Bender A, Schmierer K, Valdueza JM(2003). Diffuse cerebral angiomatosis. Neurology vol. 60, (7) 1216-1218.
10.1212/01.WNL.0000055923.78277.9C
Dobson-Stone C, Danek A, Rampoldi L, Hardie RJ, Chalmers RM, Wood NW, Bohlega S, Dotti MT et al.(2002). Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. EUR J HUM GENET vol. 10, (11) 773-+.
10.1038/sj/ejhg.5200866
Dobson-Stone C, Danek A, Rampoldi L, Hardie RJ, Chalmers RM, Wood NW, Bohlega S, Dotti MT et al.(2002). Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet vol. 10, (11) 773-781.
10.1038/sj.ejhg.5200866
Schmierer K, Irlbacher K, Grosse P, Röricht S, Meyer B-U(2002). Correlates of disability in multiple sclerosis detected by transcranial magnetic stimulation. Neurology vol. 59, (8) 1218-1224.
10.1212/WNL.59.8.1218
Schmierer K, Grosse P, De Camilli P, Solimena M, Floyd S, Zschenderlein R(2002). Paraneoplastic stiff-person syndrome: no tumor progression over 5 years. Neurology vol. 58, (1)
10.1212/WNL.58.1.148
Schmierer K(2002). [Medical history and politics: careers of Fritz Lejeune during the Weimar Republic and national socialism]. Abh Gesch Med Naturwiss (96) 1-292.
Schmierer K, Niehaus L, Röricht S, Meyer BU(2000). Conduction deficits of callosal fibres in early multiple sclerosis. J Neurol Neurosurg Psychiatry vol. 68, (5) 633-638.
10.1136/jnnp.68.5.633
Wendling U, Aktas O, Schmierer K, Zschenderlein R, Zipp F(2000). Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells--implications for multiple sclerosis. J Neuroimmunol vol. 103, (1) 69-75.
10.1016/S0165-5728(99)00214-3
Meyer BU, Röricht S, Schmierer K, Irlbacher K, Meierkord H, Niehaus L, Grosse P (1999). First diagnostic applications of transcallosal inhibition in diseases affecting callosal neurones (multiple sclerosis, hydrocephalus, Huntington's disease). Electroencephalogr Clin Neurophysiol Suppl. vol. 51, 233-242.
Kappos L, Polman C, Pozzilli C, Thompson A, Dahlke F, Knight R, Hern J, Coleman R et al.(1998). Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. LANCET vol. 352, (9139) 1491-1497.
10.1016/S0140-6736(98)10039-9
Schmierer K, Valdueza JM, Bender A, DeCamilli P, David C, Solimena M, Zschenderlein R(1998). Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression. Neurology vol. 51, (1) 250-252.
10.1212/WNL.51.1.250
Schmierer K, Roricht S, Niehaus L, Meyer BU (1998). Impaired transcallosal inhibition: an early indicator of central conduction deficits in multiple sclerosis. 9TH EUROPEAN CONGRESS OF CLINICAL NEUROPHYSIOLOGY. Editors: Stalberg, EV, DeWeerd, AW, Zidar, J, 119-123.
Meyer BU, Niehaus L, Petrow E, Schmierer K, Roricht S, Kuhn A, Irlbacher K (1998). Inhibitory effects of transcranial magnetic motor cortex stimulation in man. 9TH EUROPEAN CONGRESS OF CLINICAL NEUROPHYSIOLOGY. Editors: Stalberg, EV, DeWeerd, AW, Zidar, J, 83-88.
Valdueza JM, Schmierer K, Mehraein S, Einhäupl KM(1996). Assessment of normal flow velocity in basal cerebral veins. A transcranial doppler ultrasound study. Stroke vol. 27, (7) 1221-1225.
10.1161/01.STR.27.7.1221
Return to top